All In Biotech

Drug Trial Radar · NCT02054130

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma

Last checked: Nov 20, 2026Latest source record: Dec 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 584 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

584

Actual

Start

Dec 13, 2013

Primary completion

Dec 12, 2016

Study completion Mar 1, 2017

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Feb 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Conditions

  • Asthma

Interventions

  • PlaceboDrug

    Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

  • MEDI9929 70 mgDrug

    Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

  • MEDI9929 210 mgDrug

    Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

  • MEDI9929 280 mgDrug

    Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Asthma Exacerbation Rate (AER) Through Week 52Time frame: Week 0 (Day 1) up to Week 52

Locations

107 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Miami, Florida

  • Research Site

    Oviedo, Florida

  • Research Site

    Savannah, Georgia

  • Research Site

    Peoria, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Rochester, Minnesota

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Dublin, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Rock Hill, South Carolina

  • Research Site

    Spartanburg, South Carolina

  • Research Site

    Houston, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Velingrad, Bulgaria

  • Research Site

    Brandýs nad Labem, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Mladá Boleslav, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Strakonice, Czechia

  • Research Site

    Balassagyarmat, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Csorna, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Farkasgyepü, Hungary

  • Research Site

    Gödöllő, Hungary

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.